These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 20189560)
1. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Trolle B; Lauszus FF; Frystyk J; Flyvbjerg A Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560 [TBL] [Abstract][Full Text] [Related]
2. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study. Singh S; Akhtar N; Ahmad J Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Trolle B; Flyvbjerg A; Kesmodel U; Lauszus FF Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923 [TBL] [Abstract][Full Text] [Related]
4. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Bridger T; MacDonald S; Baltzer F; Rodd C Arch Pediatr Adolesc Med; 2006 Mar; 160(3):241-6. PubMed ID: 16520442 [TBL] [Abstract][Full Text] [Related]
5. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Chou KH; von Eye Corleta H; Capp E; Spritzer PM Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787 [TBL] [Abstract][Full Text] [Related]
6. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298 [TBL] [Abstract][Full Text] [Related]
7. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189 [TBL] [Abstract][Full Text] [Related]
8. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765 [TBL] [Abstract][Full Text] [Related]
9. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Ardawi MS; Rouzi AA Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640 [TBL] [Abstract][Full Text] [Related]
10. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089 [TBL] [Abstract][Full Text] [Related]
11. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373 [TBL] [Abstract][Full Text] [Related]
12. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. Kriplani A; Agarwal N J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709 [TBL] [Abstract][Full Text] [Related]
13. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA; Shin SY; Yoon BK; Choi D Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414 [TBL] [Abstract][Full Text] [Related]
14. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091 [TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080 [TBL] [Abstract][Full Text] [Related]
16. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811 [TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241 [TBL] [Abstract][Full Text] [Related]
18. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342 [TBL] [Abstract][Full Text] [Related]
19. Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. Hamed HO J Obstet Gynaecol Res; 2013 Dec; 39(12):1596-603. PubMed ID: 23875783 [TBL] [Abstract][Full Text] [Related]
20. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Liao L; Tian YJ; Zhao JJ; Xin Y; Xing HY; Dong JJ Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]